<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04659551</url>
  </required_header>
  <id_info>
    <org_study_id>GIADA Trial</org_study_id>
    <secondary_id>2016-004665-10</secondary_id>
    <nct_id>NCT04659551</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients</brief_title>
  <acronym>GIADA</acronym>
  <official_title>Engaging the Immune System to Improve the Efficacy of Neoadjuvant Chemo-endocrine Therapy for Premenopausal Luminal B Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Oncologico Veneto IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Oncologico Veneto IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentric, phase II neoadjuvant trial in hormone-positive, HER-negative, luminal B,&#xD;
      premenopausal breast cancer patients stage II-IIIA. Patients receive as neoadjuvant treatment&#xD;
      before surgery: three courses of anthracycline-based chemotherapy followed by exemestane p.o.&#xD;
      daily plus nivolumab i.v. 2-weekly for 8 courses. GnRH analogues are started concomitantly&#xD;
      with chemotherapy and maintained until the completion of neoadjuvant treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, phase II neoadjuvant trial in hormone-sensitive, HER-negative, luminal&#xD;
      B, premenopausal breast cancer patients stage II-IIIA.&#xD;
&#xD;
      Patients will undergo a core-biopsy of the primary tumor, for the histological diagnosis and&#xD;
      the biological characterization of the tumor.&#xD;
&#xD;
      After confirmation of eligibility and informed consent signature, the patients will start&#xD;
      neoadjuvant treatment including:&#xD;
&#xD;
      Epirubicin 90 mg/mq + Cyclophosphamide 600 mg/mq i.v. every 3 weeks for 3 courses, followed&#xD;
      by the combination of Nivolumab (240 mg flat dose i.v. each 2 weeks) for 8 courses and&#xD;
      exemestane 25 mg (orally, continuous daily dose, to be continued until surgery). Patients&#xD;
      will start LHRH analogue (Triptorelin 3.75mg 1 fl i.m. every 28 days) concomitantly to&#xD;
      anthracycline-based chemotherapy, to be continued until surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 5, 2017</start_date>
  <completion_date type="Actual">May 25, 2020</completion_date>
  <primary_completion_date type="Actual">May 25, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathological complete response (pCR)</measure>
    <time_frame>up to 7 months from enrolment</time_frame>
    <description>ypT0ypN0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical objective response</measure>
    <time_frame>up to 6 months from enrolment</time_frame>
    <description>cOR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>molecular response</measure>
    <time_frame>up to 7 months from enrolment</time_frame>
    <description>Ki67</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast conserving surgery</measure>
    <time_frame>up to 7 months from enrolment</time_frame>
    <description>Surgery type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>up to 100 days from last nivolumab dose</time_frame>
    <description>Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlative biomarkers</measure>
    <time_frame>Tumor samples will be collected at baseline, at 14 days after completion of anthracycline-based chemotherapy (about 7 weeks after first dose of Epirubicin), at surgery (about 30 weeks after first dose of Epirubicin)</time_frame>
    <description>correlation between different biomarkers expression at baseline and pathological response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epirubicin 90 mg/mq + Cyclophosphamide 600 mg/mq i.v. every 3 weeks for 3 courses, followed by Nivolumab (240 mg flat dose i.v. each 2 weeks) for 8 courses plus exemestane 25 mg (orally, continuous daily dose, to be continued until surgery). LHRH analogue (Triptorelin 3.75mg 1 fl i.m. every 28 days) started concomitantly to anthracycline based chemotherapy, to be continued until surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>Epirubicin 90 mg/mq i.v. every 3 weeks for three cycles</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamid 600 mg/mq i.v. every 3 weeks for three cycles</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin</intervention_name>
    <description>Triptorelin 3.75 mg i.m. every 4 weeks until surgery</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Exemestane 25 mg oral continuous daily dose until surgery</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 240 mg flat dose i.v. every two weeks for 8 cycles</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>BMS-936558</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients may be included in the study only if they met all the following criteria&#xD;
&#xD;
          -  age &gt;18 yrs&#xD;
&#xD;
          -  female patients&#xD;
&#xD;
          -  ECOG Performance Status 0-1&#xD;
&#xD;
          -  must have signed and dated an IRB/IEC-approved written informed consent form in&#xD;
             accordance with regulatory and institutional guidelines before the performance of any&#xD;
             protocol-related procedures&#xD;
&#xD;
          -  Primary diagnosis of invasive breast cancer, HR positive (ER ≥ 10% and/or PgR ≥10% by&#xD;
             IHC) and HER2 negative (IHC 0/1+ and/or FISH/CISH negative) according to local&#xD;
             assessment.&#xD;
&#xD;
          -  Histologic grade 3 and/or Ki67 &gt;20% according to local assessment.&#xD;
&#xD;
          -  Stage II-IIIA&#xD;
&#xD;
          -  Eligible for neoadjuvant chemotherapy according to multidisciplinary evaluation.&#xD;
&#xD;
          -  Premenopausal status&#xD;
&#xD;
          -  Normal organ and marrow function&#xD;
&#xD;
          -  Availability of tumor tissue suitable for biological and molecular examination before&#xD;
             starting primary treatment&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Patients will be excluded from the study for any of the following reasons&#xD;
&#xD;
          -  Stage IIIB, IIIC, and inflammatory breast cancer&#xD;
&#xD;
          -  Stage IV breast cancer&#xD;
&#xD;
          -  Prior treatment with chemotherapy, biologic therapy, endocrine therapy or radiotherapy&#xD;
             for the treatment of the newly-diagnosed breast cancer.&#xD;
&#xD;
          -  Contraindication to anthracycline-based chemotherapy.&#xD;
&#xD;
          -  Received any investigational treatment within 4 weeks of study start.&#xD;
&#xD;
          -  Any other concurrent chemotherapy, biologic therapy, endocrine therapy or radiotherapy&#xD;
             for cancer treatment.&#xD;
&#xD;
          -  Known HIV, HBV, HCV infection or any positive tests for HBV and HCV indicating acute&#xD;
             or chronic infection.&#xD;
&#xD;
          -  Known severe hypersensitivity to any of the study drugs or excipients or known severe&#xD;
             hypersensitivity reactions to monoclonal antibodies.&#xD;
&#xD;
          -  Major surgical procedure or significant traumatic injury within 28 days prior to&#xD;
             treatment initiation or anticipation of need for major surgery during the course of&#xD;
             study treatment.&#xD;
&#xD;
          -  History of allogenic organ transplantation&#xD;
&#xD;
          -  Clinically significant (that is, active) cardiovascular disease: cerebral vascular&#xD;
             accident /stroke (&lt; 6 months prior to enrollment), myocardial infarction (&lt; 6 months&#xD;
             prior to enrollment), unstable angina, congestive heart failure (New York Heart&#xD;
             Association Classification Class ≥ II), or serious uncontrolled cardiac arrhythmia&#xD;
             requiring medication.&#xD;
&#xD;
          -  Subjects with a condition requiring systemic treatment with either corticosteroids (&gt;&#xD;
             10 mg daily prednisone equivalent) or other immunosuppressive medications within 14&#xD;
             days of treatment initiation.&#xD;
&#xD;
          -  Subjects with active, known or suspected autoimmune disease. Subjects with type I&#xD;
             diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders&#xD;
             (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment or&#xD;
             conditions not expected to recur in the absence of an external trigger are permitted&#xD;
             to enroll.&#xD;
&#xD;
          -  Any other serious or uncontrolled medical disorder, active infection, physical exam&#xD;
             finding, laboratory finding, altered mental status, or psychiatric condition that, in&#xD;
             the opinion of the investigator, would limit a subject's ability to comply with the&#xD;
             study requirements, substantially increase risk to the subject, or impact the&#xD;
             interpretability of study results.&#xD;
&#xD;
          -  Prisoners or subjects who are involuntarily incarcerated&#xD;
&#xD;
          -  Subjects who are compulsorily detained for treatment of either a psychiatric or&#xD;
             physical (eg, infectious disease) illness&#xD;
&#xD;
          -  Lack of physical integrity of the upper gastrointestinal tract, clinically significant&#xD;
             malabsorption syndrome, or inability to take oral medication.&#xD;
&#xD;
          -  Psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  Subjects assessed by the investigator to be unable or unwilling to comply with the&#xD;
             requirements of the protocol&#xD;
&#xD;
          -  Current pregnancy and/or lactation.&#xD;
&#xD;
          -  Refusal to adopt adequate (highly effective) contraception methods.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierfranco Conte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Padova</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arcispedale S. Anna</name>
      <address>
        <city>Cona</city>
        <state>FE</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico di Aviano (CRO)</name>
      <address>
        <city>Aviano</city>
        <state>PN</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico veneto IRCCS</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 23, 2018</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

